Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2020 and earlier)

Company profile

Business Address 350 FIFTH AVENUE
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:304213100126111
Cash and cash equivalents185111793080
Short-term investments11994219731
Other undisclosed cash, cash equivalents, and short-term investments(0)7   
Deferred costs    2
Other undisclosed current assets4(4)12(1)
Total current assets:308209101128112
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment292111
Long-term investments and receivables 7   
Long-term investments 7   
Intangible assets, net (including goodwill)3131   
Goodwill3131   
Deposits noncurrent assets01   
Restricted cash and investments21   
Other noncurrent assets  000
Other undisclosed noncurrent assets0    
Total noncurrent assets:6442111
TOTAL ASSETS:372251102130113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1715474
Accounts payable4 022
Accrued liabilities11243
Employee-related liabilities32   
Interest and dividends payable1111 
Other undisclosed accounts payable and accrued liabilities811   
Debt1    
Total current liabilities:1815474
Noncurrent Liabilities
Long-term debt and lease obligation4641   
Long-term debt, excluding current maturities4541   
Operating lease, liability1
Liabilities, other than long-term debt00000
Deferred rent credit 0
Other liabilities0 000
Other undisclosed noncurrent liabilities  5049 
Total noncurrent liabilities:474250490
Total liabilities:655754565
Stockholders' equity
Stockholders' equity attributable to parent3071944873109
Common stock10000
Treasury stock, value(0)(1)   
Additional paid in capital490300316312305
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)
Accumulated deficit(183)(106)(268)(239)(196)
Total stockholders' equity:3071944873109
TOTAL LIABILITIES AND EQUITY:372251102130113

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(76)(71)(27)(42)(20)
Operating loss:(76)(71)(27)(42)(20)
Nonoperating income
(Investment Income, Nonoperating)
  100
Interest and debt expense(6)(6)(4)(1)(1)
Net loss:(82)(77)(29)(43)(22)
Other undisclosed net income (loss) attributable to parent53  (46)
Net loss attributable to parent:(77)(75)(29)(43)(68)
Preferred stock dividends and other adjustments    (0)
Net loss available to common stockholders, diluted:(77)(75)(29)(43)(68)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(82)(77)(29)(43)(22)
Other undisclosed comprehensive income (loss)  0(0)(46)
Comprehensive loss:(82)(77)(29)(43)(68)
Other undisclosed comprehensive income, net of tax, attributable to parent53   
Comprehensive loss, net of tax, attributable to parent:(77)(75)(29)(43)(68)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: